Drug Profile
CX 1001
Alternative Names: CX1001Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Unknown
- Developer Celentyx
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Haematological-malignancies in United Kingdom
- 11 Sep 2007 Phase-I clinical trials in Haematological malignancies in United Kingdom (unspecified route)